XML 140 R63.htm IDEA: XBRL DOCUMENT v3.26.1
Interests in equity-accounted investees (Tables)
12 Months Ended
Dec. 31, 2025
Disclosure of associates [abstract]  
Summary of detailed information about interest in joint venture and associates
20252024
Interests in associates$66,109 $68,223 
Summary of interests in equity accounted investees
Particulars of equity-accounted investees of the Group are as follows:
Name of an equity-accounted investeePlace of
incorporation/
operation
Particular
of issued and
paid-up capital
Proportion of nominal value of
issue capital held by the Company
Principal activity
20252024
DirectlyIndirectlyDirectlyIndirectly
%%%%
InsightaCayman Islands
2,000,000 ordinary shares
35 — 35 — Multi-cancer genetic testing services
CERBACT Asia Holdings Pte. Ltd. (“CERBACT”)Singapore
100 ordinary shares
— — — 26.04 Investment holdings
The following table summarizes the financial information of Insighta, for the years ended December 31, 2025 and 2024, as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group's interest in Insighta recognized in the consolidated financial statements.
20252024
Non-current assets$122,253 $127,005 
Current assets (including cash and cash equivalents $80,153 (2024: $81,005))
80,568 81,388 
Non-current liabilities(13,513)(14,417)
Other payables, accruals and contract liabilities(316)(238)
Amount due to a related company(110)(1,179)
Equity$188,882 $192,559 
Proportion of the Group’s interest in the associate 35 %35 %
Carrying amount of the Group’s interest in the associate$66,109 $67,396 

20252024
Other income$86 $31 
Other gains or losses266 — 
Interest income3,467 4,775 
Depreciation and amortization(5,082)(5,677)
Other expenses(3,174)(4,459)
Income tax expense836 841 
Loss for the year$(3,601)$(4,489)
Item that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations(75)597 
Total comprehensive expense for the year$(3,676)$(3,892)
Group's share of loss and total comprehensive expense$(1,286)$(1,707)
Dividends received by the Group$— $— 
Disclosure of detailed information about disposals This transaction has resulted in the recognition of a gain in profit or loss, calculated as follows:
2024
Proceeds of disposal$30,000 
Fair value of interest retained - 35%
67,954 
Carrying amount of interest on the date of disposal(96,710)
Gain recognized$1,244 
Summary of detailed information about financial information of associates
Aggregate information of associates that are not individually material:
20252024
Carrying amount of interest in CERBACT$— $827 
Group's share of (loss)/profit and total comprehensive (expense)/income(868)231